Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial

BACKGROUND: Bladder and urinary tract cancers account for approximately 21,000 new diagnoses and 5,000 deaths annually in the UK. Approximately 90% are transitional cell carcinomas where advanced disease is treated with platinum based chemotherapy and PD-1/PD-L1 directed immunotherapy. Urinary tract...

Descripción completa

Detalles Bibliográficos
Autores principales: Crabb, Simon, Wickens, Robin, Jane-Bibby, Sarah, Dunkley, Denise, Lawrence, Megan, Knight, Allen, Jones, Robert, Birtle, Alison, Huddart, Robert, Linch, Mark, Martin, Jonathan, Coleman, Adam, Boukas, Konstantinos, Markham, Hannah, Griffiths, Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510135/
https://www.ncbi.nlm.nih.gov/pubmed/37726695
http://dx.doi.org/10.1186/s12885-023-11397-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510135/
https://www.ncbi.nlm.nih.gov/pubmed/37726695
http://dx.doi.org/10.1186/s12885-023-11397-x

Ejemplares similares